Item 5.07. Submission of Matters to a Vote of Security Holders.
On June 3, 2021, Sarepta Therapeutics, Inc. (the "Company") held its annual
meeting of stockholders (the "Annual Meeting"). The following is a brief
description of each proposal voted upon at the Annual Meeting and the final
voting results for each such proposal. As of the record date for the Annual
Meeting, April 9, 2021, there were 79,746,809 shares of common stock outstanding
and entitled to vote at the Annual Meeting. There were 69,831,685 shares of
common stock entitled to vote at the Annual Meeting present online or
represented by proxy, which represented 87.57% of the outstanding shares
entitled to vote at the Annual Meeting, and which constituted a quorum for the
transaction of business.
Proposal 1: Election of Directors
The director nominees listed below were elected to serve on the Company's board
of directors as members of Class II for a term of two years. The results of the
vote were as follows:
Broker Non-
Name of Nominee For Against Abstain Votes
Richard J. Barry 52,392,357 9,172,056 32,611 8,234,661
M. Kathleen Behrens, Ph.D. 59,266,655 1,723,221 607,148 8,234,661
Claude Nicaise, M.D. 61,105,622 466,205 25,197 8,234,661
Proposal 2: Advisory Vote to Approve Named Executive Officer Compensation
The stockholders approved, on an advisory basis, the compensation of the
Company's named executive officers for 2020. The results of the advisory vote
were as follows:
For Against Abstain Broker Non-Votes
60,029,842 1,448,156 119,026 8,234,661
Proposal 3: Ratification of KPMG as the Company's Independent Registered Public
Accounting Firm
The stockholders ratified the appointment of KPMG LLP as the Company's
independent registered public accounting firm for the year ended December 31,
2021. The results of the vote were as follows:
For Against Abstain
68,895,705 879,159 56,821
2
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses